参考文献:1. Bloomgren, G, Richman, S, Hotermans, C, Subramanyam, M, Goelz, S, Natarajan, A, Lee, S, Plavina, T, Scanlon, JV, Sandrock, A, Bozic, C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: pp. 1870-1880 CrossRef 2. Hunt, D, Giovannoni, G (2012) Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 12: pp. 25-35 CrossRef 3. Foley J, Gudesblatt M, Zarif M, Lathi E (2014) Low body weight as a potential surrogate risk factor for progressive multifocal leukoencephalopathy. In: Pulst SM (ed) The 66th Annual Meeting of American Academy of Neurology. Philadelphia, 26 April鈥? May, pp P2鈥揚244 4. Khatri, BO, Man, S, Giovannoni, G, Koo, AP, Lee, JC, Tucky, B, Lynn, F, Jurgensen, S, Woodworth, J, Goelz, S, Duda, PW, Panzara, MA, Ransohoff, RM, Fox, RJ (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: pp. 402-409 CrossRef 5. Bomprezzi, R, Pawate, S (2014) Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 7: pp. 227-231 CrossRef
刊物类别:Medicine
刊物主题:Medicine & Public Health Neurology Neurosciences Neuroradiology